(2021). Persistence of Eosinophilic Asthma Endotype and Clinical Outcomes: A Real-World Observational Study. J Asthma Allergy, 14, 727-742. http://doi.org/10.2147/jaa.s306416.
(2018). Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax. http://doi.org/10.1136/thoraxjnl-2017-210531.
(2018). Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. http://doi.org/10.2147/jaa.s176026.
(2018). Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PLoS One. http://doi.org/10.1371/journal.pone.0201143.
(2019). Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. http://doi.org/10.1111/all.13556.
(2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. http://doi.org/10.1183/23120541.00188-2020.
(2020). Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. http://doi.org/10.1136/thoraxjnl-2019-214457.
(2021). Asthma phenotyping in primary care: applying the International Severe Asthma Registry eosinophil phenotype algorithm across all asthma severities. J Allergy Clin Immunol Pract. http://doi.org/10.1016/j.jaip.2021.07.056.